Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fecal Microbiota Transplantation Combined With QL1706, Bevacizumab, and XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis: A Prospective, Multi-center, Single-arm Phase II Study

NCT06801665 is registered in ClinicalTrials.gov with Hua Jiang as lead sponsor.

NCT NCT06801665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06801665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fecal Microbiota Transplantation Combined With QL1706, Bevacizumab, and XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis: A Prospective, Multi-center, Single-arm Phase II Study
Lead sponsor
Hua Jiang
Phase
Phase 2
Overall status
Recruiting
Start date
April 17, 2025
Completion date
February 1, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer liver metastasis